Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00104013 · ClinicalTrials.gov registry record · Phase 3
Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,455
- Enrollment target
NCT00104013: Completed Phase 3 study, sponsored by Sanofi.
NCT00104013 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 1,455 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00104013, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,455 participants
- Enrollment target
Study Summary
The purpose of this study is to assess xaliproden's potential capacity of slowing the deterioration of cognitive and global functions in patients with mild to moderate Alzheimer's disease. The patients participating in this study will take orally once daily xaliproden or placebo (inactive substance pill).
Interventions
- DRUG xaliproden (SR57746A)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,455 participants |
| Start Date | 2003-11 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
What the finished NCT00104013 record still lists
NCT00104013 is an interventional study that assigns participants to a tested intervention. Its 1,455 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% higher).
The record links to 0 conditions, and to 1 intervention - of which xaliproden (SR57746A) is the first listed.
NCT00104013 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00104013 about?
NCT00104013 is a clinical study titled "Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type". The purpose of this study is to assess xaliproden's potential capacity of slowing the deterioration of cognitive and global functions in patients with mild to moderate Alzheimer's disease. The patients participating in this study will take orally once daily xaliproden or placebo (inactive substance ...
What is the current status of trial NCT00104013?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,455 participants. The study started on 2003-11. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00104013?
The interventions under investigation include: xaliproden (SR57746A) (DRUG).
Who is sponsoring clinical trial NCT00104013?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00104013's enrollment target sits among peer trials
1,455 166th of 2000 higher than 1,835 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03936361 · 1,456 participants · Phase 3
Statins In Intracerbral Hemorrhage
- NCT06782347 · 1,454 participants · NA
Activating SilverSneakers Benefits for Seniors With Osteoarthritis
- NCT04566328 · 1,450 participants · Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- NCT05229341 · 1,450 participants · NA
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia